| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | mRNA 3'-UTR binding | HNRNPA0 HNRNPA1 HNRNPA1L3 HNRNPA2B1 HNRNPA1L2 FUS ILF3 HNRNPA3 | 1.41e-11 | 276 | 16 | 8 | GO:0003730 |
| GeneOntologyMolecularFunction | mRNA binding | HNRNPA0 HNRNPA1 HNRNPA1L3 HNRNPA2B1 DDX3Y HNRNPA1L2 DDX3X FUS ILF3 HNRNPA3 | 1.60e-11 | 694 | 16 | 10 | GO:0003729 |
| GeneOntologyMolecularFunction | RNA strand annealing activity | 4.22e-09 | 5 | 16 | 3 | GO:0033592 | |
| GeneOntologyMolecularFunction | G-rich strand telomeric DNA binding | 6.94e-08 | 11 | 16 | 3 | GO:0098505 | |
| GeneOntologyMolecularFunction | single-stranded telomeric DNA binding | 1.20e-07 | 13 | 16 | 3 | GO:0043047 | |
| GeneOntologyMolecularFunction | annealing activity | 1.53e-07 | 14 | 16 | 3 | GO:0140666 | |
| GeneOntologyMolecularFunction | sequence-specific single stranded DNA binding | 1.91e-07 | 15 | 16 | 3 | GO:0098847 | |
| GeneOntologyMolecularFunction | single-stranded RNA binding | 1.56e-06 | 111 | 16 | 4 | GO:0003727 | |
| GeneOntologyMolecularFunction | telomeric repeat-containing RNA binding | 1.81e-06 | 3 | 16 | 2 | GO:0061752 | |
| GeneOntologyMolecularFunction | telomeric DNA binding | 4.10e-06 | 40 | 16 | 3 | GO:0042162 | |
| GeneOntologyMolecularFunction | miRNA binding | 7.14e-06 | 48 | 16 | 3 | GO:0035198 | |
| GeneOntologyMolecularFunction | regulatory RNA binding | 1.55e-05 | 62 | 16 | 3 | GO:0061980 | |
| GeneOntologyMolecularFunction | pre-mRNA binding | 1.71e-05 | 64 | 16 | 3 | GO:0036002 | |
| GeneOntologyMolecularFunction | DNA/DNA annealing activity | 3.30e-05 | 11 | 16 | 2 | GO:1990814 | |
| GeneOntologyMolecularFunction | sequence-specific mRNA binding | 1.02e-04 | 19 | 16 | 2 | GO:1990825 | |
| GeneOntologyMolecularFunction | single-stranded DNA binding | 1.55e-04 | 134 | 16 | 3 | GO:0003697 | |
| GeneOntologyMolecularFunction | mRNA 3'-UTR AU-rich region binding | 2.41e-04 | 29 | 16 | 2 | GO:0035925 | |
| GeneOntologyMolecularFunction | molecular condensate scaffold activity | 5.09e-04 | 42 | 16 | 2 | GO:0140693 | |
| GeneOntologyMolecularFunction | RNA helicase activity | 1.74e-03 | 78 | 16 | 2 | GO:0003724 | |
| GeneOntologyMolecularFunction | ATP-dependent activity, acting on RNA | 1.83e-03 | 80 | 16 | 2 | GO:0008186 | |
| GeneOntologyMolecularFunction | helicase activity | 6.94e-03 | 158 | 16 | 2 | GO:0004386 | |
| GeneOntologyBiologicalProcess | RNA splicing | HNRNPA1 HNRNPA1L3 HNRNPA2B1 FAM98A HNRNPH3 HNRNPA1L2 FUS HNRNPUL1 HNRNPA3 | 2.74e-11 | 502 | 16 | 9 | GO:0008380 |
| GeneOntologyBiologicalProcess | RNA processing | HNRNPA0 HNRNPA1 HNRNPA1L3 HNRNPA2B1 FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS HNRNPUL1 HNRNPA3 | 9.02e-10 | 1500 | 16 | 11 | GO:0006396 |
| GeneOntologyBiologicalProcess | mRNA processing | HNRNPA0 HNRNPA1 HNRNPA1L3 HNRNPA2B1 HNRNPH3 HNRNPA1L2 HNRNPUL1 HNRNPA3 | 2.63e-09 | 551 | 16 | 8 | GO:0006397 |
| GeneOntologyBiologicalProcess | mRNA splicing, via spliceosome | HNRNPA1 HNRNPA1L3 HNRNPA2B1 HNRNPH3 HNRNPA1L2 HNRNPUL1 HNRNPA3 | 4.48e-09 | 358 | 16 | 7 | GO:0000398 |
| GeneOntologyBiologicalProcess | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | HNRNPA1 HNRNPA1L3 HNRNPA2B1 HNRNPH3 HNRNPA1L2 HNRNPUL1 HNRNPA3 | 4.48e-09 | 358 | 16 | 7 | GO:0000377 |
| GeneOntologyBiologicalProcess | RNA splicing, via transesterification reactions | HNRNPA1 HNRNPA1L3 HNRNPA2B1 HNRNPH3 HNRNPA1L2 HNRNPUL1 HNRNPA3 | 4.83e-09 | 362 | 16 | 7 | GO:0000375 |
| GeneOntologyBiologicalProcess | mRNA metabolic process | HNRNPA0 HNRNPA1 HNRNPA1L3 HNRNPA2B1 HNRNPH3 HNRNPA1L2 FUS HNRNPUL1 HNRNPA3 | 5.63e-09 | 917 | 16 | 9 | GO:0016071 |
| GeneOntologyBiologicalProcess | mRNA transport | 3.99e-06 | 145 | 16 | 4 | GO:0051028 | |
| GeneOntologyBiologicalProcess | RNA transport | 8.42e-06 | 175 | 16 | 4 | GO:0050658 | |
| GeneOntologyBiologicalProcess | nucleic acid transport | 8.42e-06 | 175 | 16 | 4 | GO:0050657 | |
| GeneOntologyBiologicalProcess | establishment of RNA localization | 9.00e-06 | 178 | 16 | 4 | GO:0051236 | |
| GeneOntologyBiologicalProcess | regulation of RNA splicing | 1.63e-05 | 207 | 16 | 4 | GO:0043484 | |
| GeneOntologyBiologicalProcess | RNA localization | 1.96e-05 | 217 | 16 | 4 | GO:0006403 | |
| GeneOntologyBiologicalProcess | alternative mRNA splicing, via spliceosome | 2.92e-05 | 79 | 16 | 3 | GO:0000380 | |
| GeneOntologyBiologicalProcess | nucleobase-containing compound transport | 3.37e-05 | 249 | 16 | 4 | GO:0015931 | |
| GeneOntologyBiologicalProcess | cellular response to potassium ion | 5.11e-05 | 14 | 16 | 2 | GO:0035865 | |
| GeneOntologyBiologicalProcess | positive regulation of action potential | 8.57e-05 | 18 | 16 | 2 | GO:0045760 | |
| GeneOntologyBiologicalProcess | negative regulation of mRNA metabolic process | 8.97e-05 | 115 | 16 | 3 | GO:1903312 | |
| GeneOntologyBiologicalProcess | cellular response to arsenic-containing substance | 9.57e-05 | 19 | 16 | 2 | GO:0071243 | |
| GeneOntologyBiologicalProcess | primary miRNA processing | 1.06e-04 | 20 | 16 | 2 | GO:0031053 | |
| GeneOntologyBiologicalProcess | response to potassium ion | 1.17e-04 | 21 | 16 | 2 | GO:0035864 | |
| GeneOntologyBiologicalProcess | regulation of mRNA metabolic process | 3.11e-04 | 443 | 16 | 4 | GO:1903311 | |
| GeneOntologyBiologicalProcess | response to arsenic-containing substance | 3.70e-04 | 37 | 16 | 2 | GO:0046685 | |
| GeneOntologyBiologicalProcess | positive regulation of telomere maintenance via telomere lengthening | 4.11e-04 | 39 | 16 | 2 | GO:1904358 | |
| GeneOntologyBiologicalProcess | positive regulation of gene expression | 5.10e-04 | 1446 | 16 | 6 | GO:0010628 | |
| GeneOntologyBiologicalProcess | cellular response to metal ion | 5.97e-04 | 219 | 16 | 3 | GO:0071248 | |
| GeneOntologyBiologicalProcess | miRNA processing | 6.23e-04 | 48 | 16 | 2 | GO:0035196 | |
| GeneOntologyBiologicalProcess | protein methylation | 1.18e-03 | 66 | 16 | 2 | GO:0006479 | |
| GeneOntologyBiologicalProcess | protein alkylation | 1.18e-03 | 66 | 16 | 2 | GO:0008213 | |
| GeneOntologyBiologicalProcess | regulation of telomere maintenance via telomere lengthening | 1.28e-03 | 69 | 16 | 2 | GO:1904356 | |
| GeneOntologyBiologicalProcess | positive regulation of telomere maintenance | 1.40e-03 | 72 | 16 | 2 | GO:0032206 | |
| GeneOntologyBiologicalProcess | regulatory ncRNA processing | 1.47e-03 | 74 | 16 | 2 | GO:0070918 | |
| GeneOntologyBiologicalProcess | mRNA stabilization | 1.60e-03 | 77 | 16 | 2 | GO:0048255 | |
| GeneOntologyBiologicalProcess | regulation of action potential | 1.76e-03 | 81 | 16 | 2 | GO:0098900 | |
| GeneOntologyBiologicalProcess | DNA geometric change | 1.99e-03 | 86 | 16 | 2 | GO:0032392 | |
| GeneOntologyBiologicalProcess | positive regulation of DNA metabolic process | 2.00e-03 | 333 | 16 | 3 | GO:0051054 | |
| GeneOntologyBiologicalProcess | negative regulation of mRNA catabolic process | 2.03e-03 | 87 | 16 | 2 | GO:1902373 | |
| GeneOntologyBiologicalProcess | RNA stabilization | 2.08e-03 | 88 | 16 | 2 | GO:0043489 | |
| GeneOntologyBiologicalProcess | telomere maintenance via telomere lengthening | 2.17e-03 | 90 | 16 | 2 | GO:0010833 | |
| GeneOntologyBiologicalProcess | regulation of viral genome replication | 2.22e-03 | 91 | 16 | 2 | GO:0045069 | |
| GeneOntologyBiologicalProcess | DNA conformation change | 2.37e-03 | 94 | 16 | 2 | GO:0071103 | |
| GeneOntologyBiologicalProcess | RNA export from nucleus | 2.47e-03 | 96 | 16 | 2 | GO:0006405 | |
| GeneOntologyBiologicalProcess | negative regulation of RNA catabolic process | 2.72e-03 | 101 | 16 | 2 | GO:1902369 | |
| GeneOntologyBiologicalProcess | regulation of telomere maintenance | 3.34e-03 | 112 | 16 | 2 | GO:0032204 | |
| GeneOntologyBiologicalProcess | positive regulation of chromosome organization | 3.40e-03 | 113 | 16 | 2 | GO:2001252 | |
| GeneOntologyBiologicalProcess | response to metal ion | 3.73e-03 | 415 | 16 | 3 | GO:0010038 | |
| GeneOntologyBiologicalProcess | response to virus | 3.98e-03 | 425 | 16 | 3 | GO:0009615 | |
| GeneOntologyBiologicalProcess | regulation of mRNA splicing, via spliceosome | 4.40e-03 | 129 | 16 | 2 | GO:0048024 | |
| GeneOntologyBiologicalProcess | viral genome replication | 4.94e-03 | 137 | 16 | 2 | GO:0019079 | |
| GeneOntologyBiologicalProcess | regulation of DNA biosynthetic process | 5.02e-03 | 138 | 16 | 2 | GO:2000278 | |
| GeneOntologyBiologicalProcess | macromolecule methylation | 5.52e-03 | 145 | 16 | 2 | GO:0043414 | |
| GeneOntologyBiologicalProcess | regulation of viral life cycle | 6.36e-03 | 156 | 16 | 2 | GO:1903900 | |
| GeneOntologyBiologicalProcess | regulation of mRNA processing | 6.52e-03 | 158 | 16 | 2 | GO:0050684 | |
| GeneOntologyBiologicalProcess | telomere maintenance | 7.34e-03 | 168 | 16 | 2 | GO:0000723 | |
| GeneOntologyBiologicalProcess | regulation of DNA metabolic process | 8.73e-03 | 564 | 16 | 3 | GO:0051052 | |
| GeneOntologyBiologicalProcess | nuclear export | 8.84e-03 | 185 | 16 | 2 | GO:0051168 | |
| GeneOntologyBiologicalProcess | regulation of viral process | 8.93e-03 | 186 | 16 | 2 | GO:0050792 | |
| GeneOntologyCellularComponent | ribonucleoprotein complex | HNRNPA0 HNRNPA1 HNRNPA1L3 HNRNPA2B1 HNRNPH3 HNRNPA1L2 DDX3X ILF3 HNRNPUL1 HNRNPA3 | 2.08e-09 | 1194 | 16 | 10 | GO:1990904 |
| GeneOntologyCellularComponent | spliceosomal complex | 8.11e-09 | 215 | 16 | 6 | GO:0005681 | |
| GeneOntologyCellularComponent | catalytic step 2 spliceosome | 8.13e-09 | 97 | 16 | 5 | GO:0071013 | |
| GeneOntologyCellularComponent | nucleoplasmic periphery of the nuclear pore complex | 8.22e-06 | 6 | 16 | 2 | GO:1990826 | |
| GeneOntologyCellularComponent | ribonucleoprotein granule | 5.56e-05 | 287 | 16 | 4 | GO:0035770 | |
| GeneOntologyCellularComponent | pole plasm | 2.20e-04 | 29 | 16 | 2 | GO:0045495 | |
| GeneOntologyCellularComponent | germ plasm | 2.20e-04 | 29 | 16 | 2 | GO:0060293 | |
| GeneOntologyCellularComponent | P granule | 2.20e-04 | 29 | 16 | 2 | GO:0043186 | |
| GeneOntologyCellularComponent | nuclear protein-containing complex | 3.64e-04 | 1377 | 16 | 6 | GO:0140513 | |
| GeneOntologyCellularComponent | postsynaptic cytosol | 5.33e-04 | 45 | 16 | 2 | GO:0099524 | |
| GeneOntologyCellularComponent | cytoplasmic ribonucleoprotein granule | 1.04e-03 | 269 | 16 | 3 | GO:0036464 | |
| GeneOntologyCellularComponent | cytosolic region | 1.29e-03 | 70 | 16 | 2 | GO:0099522 | |
| GeneOntologyCellularComponent | perikaryon | 1.23e-02 | 223 | 16 | 2 | GO:0043204 | |
| HumanPheno | Dyscalculia | 9.14e-07 | 24 | 5 | 3 | HP:0002442 | |
| HumanPheno | Ubiquitin-positive cerebral inclusion bodies | 2.31e-06 | 3 | 5 | 2 | HP:0012083 | |
| HumanPheno | Amyotrophic lateral sclerosis | 8.25e-06 | 49 | 5 | 3 | HP:0007354 | |
| HumanPheno | Frontotemporal dementia | 9.89e-06 | 52 | 5 | 3 | HP:0002145 | |
| HumanPheno | Mutism | 1.24e-05 | 56 | 5 | 3 | HP:0002300 | |
| HumanPheno | Motor neuron atrophy | 2.04e-05 | 66 | 5 | 3 | HP:0007373 | |
| HumanPheno | Calvarial hyperostosis | 3.46e-05 | 10 | 5 | 2 | HP:0004490 | |
| HumanPheno | Generalized amyotrophy | 4.54e-05 | 86 | 5 | 3 | HP:0003700 | |
| HumanPheno | Hip pain | 5.07e-05 | 12 | 5 | 2 | HP:0030838 | |
| HumanPheno | Fasciculations | 1.79e-04 | 136 | 5 | 3 | HP:0002380 | |
| HumanPheno | Dysphonia | 2.85e-04 | 159 | 5 | 3 | HP:0001618 | |
| HumanPheno | EMG: chronic denervation signs | 2.88e-04 | 28 | 5 | 2 | HP:0003444 | |
| HumanPheno | Urinary bladder sphincter dysfunction | 3.78e-04 | 32 | 5 | 2 | HP:0002839 | |
| HumanPheno | Proximal muscle weakness in lower limbs | 4.54e-04 | 186 | 5 | 3 | HP:0008994 | |
| HumanPheno | Progressive distal muscular atrophy | 5.34e-04 | 38 | 5 | 2 | HP:0008955 | |
| HumanPheno | Motor axonal neuropathy | 5.34e-04 | 38 | 5 | 2 | HP:0007002 | |
| HumanPheno | Sensory axonal neuropathy | 5.63e-04 | 39 | 5 | 2 | HP:0003390 | |
| HumanPheno | Fatty replacement of skeletal muscle | 5.63e-04 | 39 | 5 | 2 | HP:0012548 | |
| HumanPheno | Jaw hyperreflexia | 6.23e-04 | 41 | 5 | 2 | HP:0033683 | |
| HumanPheno | Fatigable weakness of swallowing muscles | 6.53e-04 | 42 | 5 | 2 | HP:0030195 | |
| HumanPheno | Laryngospasm | 6.53e-04 | 42 | 5 | 2 | HP:0025425 | |
| HumanPheno | Hoffmann sign | 7.84e-04 | 46 | 5 | 2 | HP:0031993 | |
| HumanPheno | Rimmed vacuoles | 7.84e-04 | 46 | 5 | 2 | HP:0003805 | |
| HumanPheno | Dementia | 7.96e-04 | 225 | 5 | 3 | HP:0000726 | |
| HumanPheno | Abnormality of cognition | 7.96e-04 | 225 | 5 | 3 | HP:0002302 | |
| HumanPheno | Abnormal larynx physiology | 8.54e-04 | 48 | 5 | 2 | HP:0025424 | |
| HumanPheno | Cranial nerve compression | 9.64e-04 | 51 | 5 | 2 | HP:0001293 | |
| HumanPheno | Cerebral inclusion bodies | 9.64e-04 | 51 | 5 | 2 | HP:0100314 | |
| HumanPheno | Tongue atrophy | 1.00e-03 | 52 | 5 | 2 | HP:0012473 | |
| HumanPheno | Cranial hyperostosis | 1.04e-03 | 53 | 5 | 2 | HP:0004437 | |
| HumanPheno | EMG: neuropathic changes | 1.08e-03 | 54 | 5 | 2 | HP:0003445 | |
| HumanPheno | Xerostomia | 1.12e-03 | 55 | 5 | 2 | HP:0000217 | |
| HumanPheno | Increased skull ossification | 1.25e-03 | 58 | 5 | 2 | HP:0004330 | |
| HumanPheno | Fatigable weakness of respiratory muscles | 1.25e-03 | 58 | 5 | 2 | HP:0030196 | |
| HumanPheno | Pathologic fracture | 1.29e-03 | 59 | 5 | 2 | HP:0002756 | |
| HumanPheno | Abnormality of the larynx | 1.30e-03 | 666 | 5 | 4 | HP:0001600 | |
| HumanPheno | Centrally nucleated skeletal muscle fibers | 1.33e-03 | 60 | 5 | 2 | HP:0003687 | |
| HumanPheno | Hyperostosis | 1.38e-03 | 61 | 5 | 2 | HP:0100774 | |
| HumanPheno | Fatigable weakness of bulbar muscles | 1.38e-03 | 61 | 5 | 2 | HP:0030192 | |
| HumanPheno | Muscle fiber atrophy | 1.66e-03 | 67 | 5 | 2 | HP:0100295 | |
| HumanPheno | Abnormality of the musculature of the lower limbs | 1.80e-03 | 297 | 5 | 3 | HP:0001437 | |
| HumanPheno | Abnormal muscle fiber morphology | 1.89e-03 | 302 | 5 | 3 | HP:0004303 | |
| HumanPheno | Tongue fasciculations | 2.02e-03 | 74 | 5 | 2 | HP:0001308 | |
| HumanPheno | Osteolysis | 2.60e-03 | 84 | 5 | 2 | HP:0002797 | |
| HumanPheno | Specific learning disability | 2.62e-03 | 338 | 5 | 3 | HP:0001328 | |
| HumanPheno | Proximal muscle weakness | 2.66e-03 | 340 | 5 | 3 | HP:0003701 | |
| HumanPheno | Brain atrophy | 2.67e-03 | 802 | 5 | 4 | HP:0012444 | |
| HumanPheno | Brain very small | 2.67e-03 | 802 | 5 | 4 | HP:0001322 | |
| HumanPheno | Neurodegeneration | 2.73e-03 | 86 | 5 | 2 | HP:0002180 | |
| HumanPheno | Distal muscle weakness | 2.99e-03 | 354 | 5 | 3 | HP:0002460 | |
| HumanPheno | Limb muscle weakness | 3.12e-03 | 359 | 5 | 3 | HP:0003690 | |
| HumanPheno | Steppage gait | 3.25e-03 | 94 | 5 | 2 | HP:0003376 | |
| HumanPheno | Abnormality of skull ossification | 3.25e-03 | 94 | 5 | 2 | HP:0002703 | |
| HumanPheno | Cerebral hypoplasia | 3.25e-03 | 844 | 5 | 4 | HP:0006872 | |
| HumanPheno | Muscle fibrillation | 3.46e-03 | 97 | 5 | 2 | HP:0010546 | |
| HumanPheno | Spastic paraparesis | 3.53e-03 | 98 | 5 | 2 | HP:0002313 | |
| HumanPheno | Cachexia | 3.67e-03 | 100 | 5 | 2 | HP:0004326 | |
| HumanPheno | Inability to walk | 3.82e-03 | 385 | 5 | 3 | HP:0002540 | |
| HumanPheno | Psychomotor regression | 3.96e-03 | 390 | 5 | 3 | HP:0002489 | |
| HumanPheno | Mental deterioration | 3.96e-03 | 390 | 5 | 3 | HP:0001268 | |
| HumanPheno | Aphasia | 3.97e-03 | 104 | 5 | 2 | HP:0002381 | |
| HumanPheno | Orthopnea | 4.27e-03 | 108 | 5 | 2 | HP:0012764 | |
| HumanPheno | Paraparesis | 4.75e-03 | 114 | 5 | 2 | HP:0002385 | |
| HumanPheno | Abnormal tongue physiology | 4.83e-03 | 115 | 5 | 2 | HP:0030810 | |
| HumanPheno | Increased variability in muscle fiber diameter | 4.92e-03 | 116 | 5 | 2 | HP:0003557 | |
| HumanPheno | Weakness of muscles of respiration | 4.92e-03 | 116 | 5 | 2 | HP:0004347 | |
| HumanPheno | Elevated circulating alkaline phosphatase concentration | 5.08e-03 | 118 | 5 | 2 | HP:0003155 | |
| HumanPheno | Abnormality of skeletal muscle fiber size | 5.34e-03 | 121 | 5 | 2 | HP:0012084 | |
| HumanPheno | Fatigable weakness | 5.34e-03 | 121 | 5 | 2 | HP:0003473 | |
| HumanPheno | Respiratory insufficiency | 5.37e-03 | 962 | 5 | 4 | HP:0002093 | |
| HumanPheno | Abnormal synaptic transmission at the neuromuscular junction | 5.43e-03 | 122 | 5 | 2 | HP:0003398 | |
| HumanPheno | Abnormal peripheral nervous system synaptic transmission | 5.43e-03 | 122 | 5 | 2 | HP:0030191 | |
| HumanPheno | Abnormal synaptic transmission | 5.43e-03 | 122 | 5 | 2 | HP:0012535 | |
| HumanPheno | Feeding difficulties | 5.82e-03 | 982 | 5 | 4 | HP:0002022 | |
| HumanPheno | EMG: myopathic abnormalities | 6.05e-03 | 129 | 5 | 2 | HP:0003458 | |
| HumanPheno | Waddling gait | 6.15e-03 | 130 | 5 | 2 | HP:0002515 | |
| HumanPheno | Abnormality of alkaline phosphatase level | 6.24e-03 | 131 | 5 | 2 | HP:0004379 | |
| HumanPheno | Generalized muscle weakness | 6.52e-03 | 134 | 5 | 2 | HP:0003324 | |
| HumanPheno | Limb joint contracture | 6.73e-03 | 469 | 5 | 3 | HP:0003121 | |
| HumanPheno | Foot dorsiflexor weakness | 7.50e-03 | 144 | 5 | 2 | HP:0009027 | |
| HumanPheno | Loss of ambulation | 7.61e-03 | 145 | 5 | 2 | HP:0002505 | |
| MousePheno | abnormal intercostal muscle morphology | 8.36e-08 | 15 | 9 | 3 | MP:0002280 | |
| MousePheno | tongue muscle hypoplasia | 3.68e-07 | 2 | 9 | 2 | MP:0030421 | |
| MousePheno | skeletal muscle hypoplasia | 3.68e-06 | 5 | 9 | 2 | MP:0009460 | |
| MousePheno | neonatal lethality, complete penetrance | 8.86e-06 | 534 | 9 | 5 | MP:0011087 | |
| MousePheno | perinatal lethality, complete penetrance | 3.59e-05 | 712 | 9 | 5 | MP:0011089 | |
| MousePheno | muscle hypoplasia | 3.85e-05 | 15 | 9 | 2 | MP:0000734 | |
| MousePheno | abnormal tongue muscle morphology | 4.40e-05 | 16 | 9 | 2 | MP:0004136 | |
| MousePheno | neonatal lethality | 6.26e-05 | 799 | 9 | 5 | MP:0002058 | |
| MousePheno | abnormal hypaxial muscle morphology | 8.07e-05 | 141 | 9 | 3 | MP:0003358 | |
| MousePheno | shortened PR interval | 9.26e-05 | 23 | 9 | 2 | MP:0010511 | |
| MousePheno | abnormal P wave | 1.01e-04 | 24 | 9 | 2 | MP:0004070 | |
| MousePheno | abnormal sinoatrial node conduction | 3.13e-04 | 42 | 9 | 2 | MP:0006142 | |
| MousePheno | perinatal lethality | 3.27e-04 | 1130 | 9 | 5 | MP:0002081 | |
| MousePheno | lethality during fetal growth through weaning, complete penetrance | 5.64e-04 | 1269 | 9 | 5 | MP:0011111 | |
| MousePheno | dilated cardiomyopathy | 6.40e-04 | 60 | 9 | 2 | MP:0002795 | |
| MousePheno | abnormal PR interval | 7.50e-04 | 65 | 9 | 2 | MP:0003901 | |
| MousePheno | increased systemic arterial systolic blood pressure | 9.20e-04 | 72 | 9 | 2 | MP:0006144 | |
| MousePheno | decreased skeletal muscle size | 1.16e-03 | 81 | 9 | 2 | MP:0010240 | |
| MousePheno | abnormal atrioventricular node conduction | 1.22e-03 | 83 | 9 | 2 | MP:0006141 | |
| MousePheno | abnormal heart electrocardiography waveform feature | 1.45e-03 | 377 | 9 | 3 | MP:0010508 | |
| MousePheno | abnormal skeletal muscle size | 1.53e-03 | 93 | 9 | 2 | MP:0009458 | |
| MousePheno | abnormal impulse conducting system conduction | 1.72e-03 | 400 | 9 | 3 | MP:0003137 | |
| MousePheno | cardiomyopathy | 2.09e-03 | 109 | 9 | 2 | MP:0005330 | |
| MousePheno | abnormal suckling behavior | 2.25e-03 | 113 | 9 | 2 | MP:0001436 | |
| MousePheno | abnormal tongue morphology | 2.45e-03 | 118 | 9 | 2 | MP:0000762 | |
| MousePheno | increased heart rate | 2.53e-03 | 120 | 9 | 2 | MP:0002626 | |
| MousePheno | decreased skeletal muscle mass | 3.01e-03 | 131 | 9 | 2 | MP:0004819 | |
| MousePheno | abnormal skeletal muscle morphology | 3.40e-03 | 508 | 9 | 3 | MP:0000759 | |
| MousePheno | abnormal skeletal muscle mass | 3.87e-03 | 149 | 9 | 2 | MP:0004817 | |
| MousePheno | dilated heart ventricle | 4.02e-03 | 152 | 9 | 2 | MP:0008022 | |
| MousePheno | increased systemic arterial blood pressure | 4.34e-03 | 158 | 9 | 2 | MP:0002842 | |
| MousePheno | abnormal gas homeostasis | 5.44e-03 | 600 | 9 | 3 | MP:0003948 | |
| Domain | RRM_1 | 6.17e-11 | 208 | 14 | 7 | PF00076 | |
| Domain | RRM | 8.31e-11 | 217 | 14 | 7 | SM00360 | |
| Domain | RRM_dom | 1.14e-10 | 227 | 14 | 7 | IPR000504 | |
| Domain | RRM | 1.25e-10 | 230 | 14 | 7 | PS50102 | |
| Domain | - | 1.89e-10 | 244 | 14 | 7 | 3.30.70.330 | |
| Domain | Nucleotide-bd_a/b_plait | 2.80e-10 | 258 | 14 | 7 | IPR012677 | |
| Domain | HnRNPA1 | 3.35e-10 | 3 | 14 | 3 | IPR021662 | |
| Domain | HnRNPA1 | 3.35e-10 | 3 | 14 | 3 | PF11627 | |
| Domain | DEAD_ATP_HELICASE | 2.40e-04 | 31 | 14 | 2 | PS00039 | |
| Domain | RNA-helicase_DEAD-box_CS | 2.72e-04 | 33 | 14 | 2 | IPR000629 | |
| Domain | RNA_helicase_DEAD_Q_motif | 3.42e-04 | 37 | 14 | 2 | IPR014014 | |
| Domain | Q_MOTIF | 3.42e-04 | 37 | 14 | 2 | PS51195 | |
| Domain | DEAD | 1.33e-03 | 73 | 14 | 2 | PF00270 | |
| Domain | DEAD/DEAH_box_helicase_dom | 1.33e-03 | 73 | 14 | 2 | IPR011545 | |
| Domain | Homeobox_metazoa | 2.01e-03 | 90 | 14 | 2 | IPR020479 | |
| Domain | Helicase_C | 2.83e-03 | 107 | 14 | 2 | PF00271 | |
| Domain | HELICc | 2.83e-03 | 107 | 14 | 2 | SM00490 | |
| Domain | Helicase_C | 2.88e-03 | 108 | 14 | 2 | IPR001650 | |
| Domain | DEXDc | 2.93e-03 | 109 | 14 | 2 | SM00487 | |
| Domain | HELICASE_CTER | 2.93e-03 | 109 | 14 | 2 | PS51194 | |
| Domain | HELICASE_ATP_BIND_1 | 2.93e-03 | 109 | 14 | 2 | PS51192 | |
| Domain | Helicase_ATP-bd | 2.99e-03 | 110 | 14 | 2 | IPR014001 | |
| Domain | Homeobox_CS | 8.30e-03 | 186 | 14 | 2 | IPR017970 | |
| Domain | Homeobox | 1.29e-02 | 234 | 14 | 2 | PF00046 | |
| Domain | HOMEOBOX_1 | 1.31e-02 | 236 | 14 | 2 | PS00027 | |
| Domain | HOX | 1.32e-02 | 237 | 14 | 2 | SM00389 | |
| Domain | Homeobox_dom | 1.34e-02 | 239 | 14 | 2 | IPR001356 | |
| Domain | HOMEOBOX_2 | 1.34e-02 | 239 | 14 | 2 | PS50071 | |
| Domain | - | 1.66e-02 | 746 | 14 | 3 | 3.40.50.300 | |
| Domain | - | 1.85e-02 | 283 | 14 | 2 | 1.10.10.60 | |
| Domain | P-loop_NTPase | 2.33e-02 | 848 | 14 | 3 | IPR027417 | |
| Domain | Homeodomain-like | 2.49e-02 | 332 | 14 | 2 | IPR009057 | |
| Pathway | WP_MRNA_PROCESSING | 1.57e-10 | 451 | 11 | 8 | MM15946 | |
| Pathway | REACTOME_MRNA_SPLICING | 2.42e-07 | 201 | 11 | 5 | MM15411 | |
| Pathway | REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA | 1.19e-06 | 277 | 11 | 5 | MM15414 | |
| Pathway | REACTOME_MRNA_SPLICING | 1.51e-05 | 212 | 11 | 4 | M14033 | |
| Pathway | REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA | 4.70e-05 | 283 | 11 | 4 | M13087 | |
| Pathway | REACTOME_METABOLISM_OF_RNA | 5.64e-05 | 612 | 11 | 5 | MM15547 | |
| Pathway | REACTOME_FGFR2_ALTERNATIVE_SPLICING | 8.41e-05 | 18 | 11 | 2 | MM15334 | |
| Pathway | WP_MRNA_PROCESSING | 1.09e-04 | 126 | 11 | 3 | M39406 | |
| Pathway | KEGG_SPLICEOSOME | 1.12e-04 | 127 | 11 | 3 | M2044 | |
| Pathway | WP_NOVEL_INTRACELLULAR_COMPONENTS_OF_RIGILIKE_RECEPTOR_PATHWAY | 9.56e-04 | 60 | 11 | 2 | M39583 | |
| Pathway | REACTOME_SIGNALING_BY_FGFR2 | 1.02e-03 | 62 | 11 | 2 | MM15256 | |
| Pathway | KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY | 1.34e-03 | 71 | 11 | 2 | M15913 | |
| Pathway | REACTOME_SIGNALING_BY_FGFR | 1.57e-03 | 77 | 11 | 2 | MM14722 | |
| Pathway | REACTOME_METABOLISM_OF_RNA | 1.70e-03 | 724 | 11 | 4 | M16843 | |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y HNRNPH3 FUS ILF3 HNRNPUL1 HNRNPA3 | 1.83e-18 | 136 | 16 | 9 | 26979993 | |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 3.53e-18 | 260 | 16 | 10 | 36199071 | |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X ILF3 HNRNPUL1 HNRNPA3 | 9.03e-17 | 109 | 16 | 8 | 29511296 | |
| Pubmed | The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers. | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 2.79e-16 | 954 | 16 | 12 | 36373674 |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 3.89e-16 | 244 | 16 | 9 | 29884807 | |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 4.56e-16 | 421 | 16 | 10 | 34650049 | |
| Pubmed | A Compendium of RNA-Binding Proteins that Regulate MicroRNA Biogenesis. | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 5.61e-16 | 254 | 16 | 9 | 28431233 |
| Pubmed | TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence. | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 5.64e-16 | 430 | 16 | 10 | 38172120 |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.12e-15 | 274 | 16 | 9 | 34244482 | |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 2.68e-15 | 1153 | 16 | 12 | 29845934 | |
| Pubmed | 3.78e-15 | 172 | 16 | 8 | 26336360 | ||
| Pubmed | The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 VSIG8 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 3.86e-15 | 807 | 16 | 11 | 22681889 |
| Pubmed | HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPA1L2 VSIG8 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 6.30e-15 | 844 | 16 | 11 | 25963833 | |
| Pubmed | 6.87e-15 | 90 | 16 | 7 | 23151878 | ||
| Pubmed | C9orf72 protein quality control by UBR5-mediated heterotypic ubiquitin chains. | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 7.51e-15 | 1257 | 16 | 12 | 37317656 |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 9.26e-15 | 346 | 16 | 9 | 25324306 | |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.54e-14 | 1335 | 16 | 12 | 29229926 | |
| Pubmed | 2.40e-14 | 216 | 16 | 8 | 37640791 | ||
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A DDX3X ILF3 HNRNPUL1 HNRNPA3 | 3.10e-14 | 223 | 16 | 8 | 20020773 | |
| Pubmed | Viral immune modulators perturb the human molecular network by common and unique strategies. | 4.26e-14 | 116 | 16 | 7 | 22810585 | |
| Pubmed | A systems-wide screen identifies substrates of the SCFβTrCP ubiquitin ligase. | 4.27e-14 | 232 | 16 | 8 | 25515538 | |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y HNRNPH3 DDX3X ILF3 HNRNPUL1 HNRNPA3 | 5.92e-14 | 425 | 16 | 9 | 21081503 | |
| Pubmed | 6.56e-14 | 52 | 16 | 6 | 26265008 | ||
| Pubmed | 6.63e-14 | 245 | 16 | 8 | 21182205 | ||
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 8.83e-14 | 713 | 16 | 10 | 29802200 | |
| Pubmed | SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9. | 1.01e-13 | 258 | 16 | 8 | 37794589 | |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.04e-13 | 725 | 16 | 10 | 27025967 | |
| Pubmed | New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules. | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPA1L2 FUS ILF3 HNRNPUL1 HNRNPA3 | 1.26e-13 | 462 | 16 | 9 | 31138677 |
| Pubmed | LINKIN, a new transmembrane protein necessary for cell adhesion. | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.77e-13 | 480 | 16 | 9 | 25437307 |
| Pubmed | 2.30e-13 | 286 | 16 | 8 | 32041737 | ||
| Pubmed | 2.65e-13 | 65 | 16 | 6 | 32521226 | ||
| Pubmed | 2.70e-13 | 22 | 16 | 5 | 12456657 | ||
| Pubmed | HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 6.11e-13 | 551 | 16 | 9 | 34728620 | |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 6.21e-13 | 552 | 16 | 9 | 36293380 | |
| Pubmed | BAP1 regulation of the key adaptor protein NCoR1 is critical for γ-globin gene repression. | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 8.15e-13 | 1318 | 16 | 11 | 30463901 |
| Pubmed | 9.24e-13 | 340 | 16 | 8 | 24332808 | ||
| Pubmed | CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality. | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPA3 | 1.41e-12 | 605 | 16 | 9 | 28977666 |
| Pubmed | Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. | 1.46e-12 | 30 | 16 | 5 | 15782174 | |
| Pubmed | TBK1 phosphorylation activates LIR-dependent degradation of the inflammation repressor TNIP1. | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.51e-12 | 949 | 16 | 10 | 36574265 |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X ILF3 HNRNPUL1 HNRNPA3 | 1.63e-12 | 615 | 16 | 9 | 31048545 | |
| Pubmed | 1.73e-12 | 88 | 16 | 6 | 26318153 | ||
| Pubmed | Identification of a USP9X Substrate NFX1-123 by SILAC-Based Quantitative Proteomics. | 2.45e-12 | 384 | 16 | 8 | 31059266 | |
| Pubmed | 2.52e-12 | 206 | 16 | 7 | 22174317 | ||
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 2.76e-12 | 652 | 16 | 9 | 31180492 | |
| Pubmed | Disruption of the lamin A and matrin-3 interaction by myopathic LMNA mutations. | 2.96e-12 | 96 | 16 | 6 | 25948554 | |
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 3.07e-12 | 660 | 16 | 9 | 32780723 | |
| Pubmed | 3.76e-12 | 9 | 16 | 4 | 12565831 | ||
| Pubmed | 6.43e-12 | 109 | 16 | 6 | 12226669 | ||
| Pubmed | 7.39e-12 | 441 | 16 | 8 | 31239290 | ||
| Pubmed | 7.60e-12 | 112 | 16 | 6 | 28416769 | ||
| Pubmed | 7.63e-12 | 241 | 16 | 7 | 23125841 | ||
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 FUS ILF3 HNRNPUL1 HNRNPA3 | 7.65e-12 | 731 | 16 | 9 | 29298432 | |
| Pubmed | 8.46e-12 | 114 | 16 | 6 | 31553912 | ||
| Pubmed | 8.93e-12 | 115 | 16 | 6 | 17332742 | ||
| Pubmed | 1.28e-11 | 122 | 16 | 6 | 29530978 | ||
| Pubmed | FGF11 induced by hypoxia interacts with HIF-1α and enhances its stability. | 1.72e-11 | 128 | 16 | 6 | 28027390 | |
| Pubmed | 1.74e-11 | 491 | 16 | 8 | 22623428 | ||
| Pubmed | 1.82e-11 | 494 | 16 | 8 | 26831064 | ||
| Pubmed | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 2.23e-11 | 1247 | 16 | 10 | 27684187 | |
| Pubmed | 2.48e-11 | 136 | 16 | 6 | 21280222 | ||
| Pubmed | Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. | 2.64e-11 | 52 | 16 | 5 | 24591637 | |
| Pubmed | The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer. | 3.98e-11 | 147 | 16 | 6 | 28977470 | |
| Pubmed | HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. | 4.15e-11 | 148 | 16 | 6 | 32538781 | |
| Pubmed | 6.91e-11 | 330 | 16 | 7 | 32529326 | ||
| Pubmed | NudCL2 regulates cell migration by stabilizing both myosin-9 and LIS1 with Hsp90. | 7.36e-11 | 333 | 16 | 7 | 32665550 | |
| Pubmed | Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90/R2TP chaperones. | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 7.71e-11 | 1415 | 16 | 10 | 28515276 |
| Pubmed | ARIH2 Is a Vif-Dependent Regulator of CUL5-Mediated APOBEC3G Degradation in HIV Infection. | 7.84e-11 | 336 | 16 | 7 | 31253590 | |
| Pubmed | Analysis of hnRNPA1, A2/B1, and A3 genes in patients with amyotrophic lateral sclerosis. | 7.99e-11 | 3 | 16 | 3 | 23827524 | |
| Pubmed | A widespread sequence-specific mRNA decay pathway mediated by hnRNPs A1 and A2/B1. | 7.99e-11 | 3 | 16 | 3 | 27151978 | |
| Pubmed | The midnolin-proteasome pathway catches proteins for ubiquitination-independent degradation. | 9.00e-11 | 604 | 16 | 8 | 37616343 | |
| Pubmed | HNRNPA0 HNRNPA2B1 FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPA3 | 9.53e-11 | 971 | 16 | 9 | 33306668 | |
| Pubmed | MYC multimers shield stalled replication forks from RNA polymerase. | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.12e-10 | 989 | 16 | 9 | 36424410 |
| Pubmed | Molecular Characterization of the Oncogene BTF3 and Its Targets in Colorectal Cancer. | 1.19e-10 | 626 | 16 | 8 | 33644029 | |
| Pubmed | Identifying biological pathways that underlie primordial short stature using network analysis. | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.53e-10 | 1024 | 16 | 9 | 24711643 |
| Pubmed | 2.22e-10 | 390 | 16 | 7 | 17643375 | ||
| Pubmed | PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation. | 2.25e-10 | 678 | 16 | 8 | 30209976 | |
| Pubmed | MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons. | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y HNRNPH3 DDX3X ILF3 HNRNPUL1 HNRNPA3 | 2.48e-10 | 1082 | 16 | 9 | 38697112 |
| Pubmed | AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis. | 2.56e-10 | 200 | 16 | 6 | 35546148 | |
| Pubmed | 2.63e-10 | 23 | 16 | 4 | 18320585 | ||
| Pubmed | Profiling of Parkin-binding partners using tandem affinity purification. | 2.80e-10 | 203 | 16 | 6 | 24244333 | |
| Pubmed | 3.13e-10 | 707 | 16 | 8 | 19738201 | ||
| Pubmed | Decrease in hnRNP A/B expression during erythropoiesis mediates a pre-mRNA splicing switch. | 3.19e-10 | 4 | 16 | 3 | 12426391 | |
| Pubmed | Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 HNRNPA1L2 ILF3 HNRNPUL1 HNRNPA3 | 3.38e-10 | 714 | 16 | 8 | 28302793 |
| Pubmed | Quantitative analysis of PPT1 interactome in human neuroblastoma cells. | 3.44e-10 | 210 | 16 | 6 | 26217791 | |
| Pubmed | 3.64e-10 | 212 | 16 | 6 | 23463506 | ||
| Pubmed | A New Cellular Interactome of SARS-CoV-2 Nucleocapsid Protein and Its Biological Implications. | 5.83e-10 | 95 | 16 | 5 | 37211047 | |
| Pubmed | Proteomic dissection of the von Hippel-Lindau (VHL) interactome. | 6.83e-10 | 98 | 16 | 5 | 21942715 | |
| Pubmed | 6.93e-10 | 236 | 16 | 6 | 36339263 | ||
| Pubmed | 7.98e-10 | 5 | 16 | 3 | 20133837 | ||
| Pubmed | 7.99e-10 | 469 | 16 | 7 | 37314180 | ||
| Pubmed | 8.47e-10 | 244 | 16 | 6 | 30349055 | ||
| Pubmed | 9.04e-10 | 809 | 16 | 8 | 32129710 | ||
| Pubmed | Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 9.31e-10 | 1257 | 16 | 9 | 36526897 |
| Pubmed | 9.94e-10 | 484 | 16 | 7 | 31995728 | ||
| Pubmed | Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents. | 1.02e-09 | 486 | 16 | 7 | 30940648 | |
| Pubmed | Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. | 1.13e-09 | 256 | 16 | 6 | 24189400 | |
| Pubmed | H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.20e-09 | 1294 | 16 | 9 | 30804502 |
| Pubmed | 1.30e-09 | 847 | 16 | 8 | 35850772 | ||
| Pubmed | Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases. | 1.37e-09 | 34 | 16 | 4 | 16611982 | |
| Pubmed | 1.99e-09 | 121 | 16 | 5 | 34029587 | ||
| Interaction | MIR20A interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 3.60e-19 | 74 | 15 | 9 | int:MIR20A |
| Interaction | MIR98 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 5.94e-19 | 78 | 15 | 9 | int:MIR98 |
| Interaction | MIR143 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 7.55e-19 | 80 | 15 | 9 | int:MIR143 |
| Interaction | MIR106A interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 1.07e-18 | 83 | 15 | 9 | int:MIR106A |
| Interaction | MIR31 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 1.20e-18 | 84 | 15 | 9 | int:MIR31 |
| Interaction | MIR7-2 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 1.20e-18 | 84 | 15 | 9 | int:MIR7-2 |
| Interaction | MIR107 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 1.34e-18 | 85 | 15 | 9 | int:MIR107 |
| Interaction | MIR18B interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 1.34e-18 | 85 | 15 | 9 | int:MIR18B |
| Interaction | MIR19B2 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 3.45e-18 | 94 | 15 | 9 | int:MIR19B2 |
| Interaction | MIRLET7F1 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 3.45e-18 | 94 | 15 | 9 | int:MIRLET7F1 |
| Interaction | MIR363 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 4.63e-18 | 97 | 15 | 9 | int:MIR363 |
| Interaction | MIR128-2 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 5.61e-18 | 99 | 15 | 9 | int:MIR128-2 |
| Interaction | MIRLET7B interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 6.76e-18 | 101 | 15 | 9 | int:MIRLET7B |
| Interaction | MIRLET7D interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 6.76e-18 | 101 | 15 | 9 | int:MIRLET7D |
| Interaction | MIR25 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 6.76e-18 | 101 | 15 | 9 | int:MIR25 |
| Interaction | MIR15B interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 8.12e-18 | 103 | 15 | 9 | int:MIR15B |
| Interaction | MIR7-1 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 8.12e-18 | 103 | 15 | 9 | int:MIR7-1 |
| Interaction | MIR34A interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 8.89e-18 | 104 | 15 | 9 | int:MIR34A |
| Interaction | MIRLET7G interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 DDX3X FUS HNRNPA3 | 2.66e-17 | 117 | 15 | 9 | int:MIRLET7G |
| Interaction | MIR138-1 interactions | 6.93e-17 | 68 | 15 | 8 | int:MIR138-1 | |
| Interaction | MIR9-3 interactions | 8.84e-17 | 70 | 15 | 8 | int:MIR9-3 | |
| Interaction | MIR140 interactions | 9.96e-17 | 71 | 15 | 8 | int:MIR140 | |
| Interaction | MIR29B1 interactions | 1.26e-16 | 73 | 15 | 8 | int:MIR29B1 | |
| Interaction | MIR18A interactions | 1.26e-16 | 73 | 15 | 8 | int:MIR18A | |
| Interaction | MIR15A interactions | 1.58e-16 | 75 | 15 | 8 | int:MIR15A | |
| Interaction | MIR16-1 interactions | 1.76e-16 | 76 | 15 | 8 | int:MIR16-1 | |
| Interaction | MIR199A2 interactions | 1.76e-16 | 76 | 15 | 8 | int:MIR199A2 | |
| Interaction | MIR7-3 interactions | 1.76e-16 | 76 | 15 | 8 | int:MIR7-3 | |
| Interaction | MIR9-2 interactions | 1.97e-16 | 77 | 15 | 8 | int:MIR9-2 | |
| Interaction | MIR200A interactions | 1.97e-16 | 77 | 15 | 8 | int:MIR200A | |
| Interaction | MIR222 interactions | 2.44e-16 | 79 | 15 | 8 | int:MIR222 | |
| Interaction | MIR1-2 interactions | 2.44e-16 | 79 | 15 | 8 | int:MIR1-2 | |
| Interaction | MIR34C interactions | 2.44e-16 | 79 | 15 | 8 | int:MIR34C | |
| Interaction | MIR145 interactions | 3.00e-16 | 81 | 15 | 8 | int:MIR145 | |
| Interaction | MIR10B interactions | 3.33e-16 | 82 | 15 | 8 | int:MIR10B | |
| Interaction | MIR199A1 interactions | 4.07e-16 | 84 | 15 | 8 | int:MIR199A1 | |
| Interaction | MIR200B interactions | 4.07e-16 | 84 | 15 | 8 | int:MIR200B | |
| Interaction | MIR16-2 interactions | 4.49e-16 | 85 | 15 | 8 | int:MIR16-2 | |
| Interaction | MIR17 interactions | 4.49e-16 | 85 | 15 | 8 | int:MIR17 | |
| Interaction | MIR93 interactions | 4.49e-16 | 85 | 15 | 8 | int:MIR93 | |
| Interaction | MIR9-1 interactions | 4.49e-16 | 85 | 15 | 8 | int:MIR9-1 | |
| Interaction | MIR20B interactions | 4.95e-16 | 86 | 15 | 8 | int:MIR20B | |
| Interaction | MIR29A interactions | 5.45e-16 | 87 | 15 | 8 | int:MIR29A | |
| Interaction | MIR141 interactions | 5.99e-16 | 88 | 15 | 8 | int:MIR141 | |
| Interaction | MIR29C interactions | 6.58e-16 | 89 | 15 | 8 | int:MIR29C | |
| Interaction | MIR221 interactions | 7.22e-16 | 90 | 15 | 8 | int:MIR221 | |
| Interaction | MIR92A2 interactions | 7.22e-16 | 90 | 15 | 8 | int:MIR92A2 | |
| Interaction | MIR200C interactions | 7.91e-16 | 91 | 15 | 8 | int:MIR200C | |
| Interaction | MIR155 interactions | 8.66e-16 | 92 | 15 | 8 | int:MIR155 | |
| Interaction | MIR128-1 interactions | 8.66e-16 | 92 | 15 | 8 | int:MIR128-1 | |
| Interaction | MIR214 interactions | 9.47e-16 | 93 | 15 | 8 | int:MIR214 | |
| Interaction | MIR205 interactions | 9.47e-16 | 93 | 15 | 8 | int:MIR205 | |
| Interaction | MIRLET7A2 interactions | 1.23e-15 | 96 | 15 | 8 | int:MIRLET7A2 | |
| Interaction | MIRLET7C interactions | 1.34e-15 | 97 | 15 | 8 | int:MIRLET7C | |
| Interaction | MIR21 interactions | 1.34e-15 | 97 | 15 | 8 | int:MIR21 | |
| Interaction | MIRLET7F2 interactions | 1.34e-15 | 97 | 15 | 8 | int:MIRLET7F2 | |
| Interaction | MIR106B interactions | 1.46e-15 | 98 | 15 | 8 | int:MIR106B | |
| Interaction | MIR19A interactions | 1.73e-15 | 100 | 15 | 8 | int:MIR19A | |
| Interaction | MIRLET7A3 interactions | 2.03e-15 | 102 | 15 | 8 | int:MIRLET7A3 | |
| Interaction | MIR19B1 interactions | 2.39e-15 | 104 | 15 | 8 | int:MIR19B1 | |
| Interaction | MIRLET7E interactions | 2.79e-15 | 106 | 15 | 8 | int:MIRLET7E | |
| Interaction | MIRLET7A1 interactions | 3.26e-15 | 108 | 15 | 8 | int:MIRLET7A1 | |
| Interaction | MIR34B interactions | 3.79e-15 | 110 | 15 | 8 | int:MIR34B | |
| Interaction | RBM45 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y HNRNPH3 FUS ILF3 HNRNPUL1 HNRNPA3 | 5.07e-15 | 207 | 15 | 9 | int:RBM45 |
| Interaction | MIRLET7I interactions | 5.09e-15 | 114 | 15 | 8 | int:MIRLET7I | |
| Interaction | HNRNPDL interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 9.06e-15 | 364 | 15 | 10 | int:HNRNPDL |
| Interaction | HEXIM1 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 2.80e-14 | 913 | 15 | 12 | int:HEXIM1 |
| Interaction | MIR29B2 interactions | 3.13e-14 | 71 | 15 | 7 | int:MIR29B2 | |
| Interaction | MIR122 interactions | 3.13e-14 | 71 | 15 | 7 | int:MIR122 | |
| Interaction | MIR429 interactions | 5.13e-14 | 76 | 15 | 7 | int:MIR429 | |
| Interaction | MIR92A1 interactions | 6.20e-14 | 78 | 15 | 7 | int:MIR92A1 | |
| Interaction | MIR451A interactions | 6.20e-14 | 78 | 15 | 7 | int:MIR451A | |
| Interaction | MIR206 interactions | 6.80e-14 | 79 | 15 | 7 | int:MIR206 | |
| Interaction | SMC5 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 8.28e-14 | 1000 | 15 | 12 | int:SMC5 |
| Interaction | TRIM31 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 8.29e-14 | 454 | 15 | 10 | int:TRIM31 |
| Interaction | MIR138-2 interactions | 1.48e-13 | 88 | 15 | 7 | int:MIR138-2 | |
| Interaction | MIR1-1 interactions | 1.75e-13 | 90 | 15 | 7 | int:MIR1-1 | |
| Interaction | GLDC interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 2.72e-13 | 321 | 15 | 9 | int:GLDC |
| Interaction | HNRNPA0 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 HNRNPA1L2 FUS ILF3 HNRNPUL1 HNRNPA3 | 5.77e-13 | 349 | 15 | 9 | int:HNRNPA0 |
| Interaction | CUL5 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 7.60e-13 | 567 | 15 | 10 | int:CUL5 |
| Interaction | CUL2 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.15e-12 | 591 | 15 | 10 | int:CUL2 |
| Interaction | NEDD8 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.68e-12 | 393 | 15 | 9 | int:NEDD8 |
| Interaction | C9orf72 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 2.23e-12 | 1319 | 15 | 12 | int:C9orf72 |
| Interaction | MATR3 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 3.19e-12 | 655 | 15 | 10 | int:MATR3 |
| Interaction | IL7R interactions | 4.34e-12 | 141 | 15 | 7 | int:IL7R | |
| Interaction | RECQL4 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 5.00e-12 | 1412 | 15 | 12 | int:RECQL4 |
| Interaction | DCUN1D1 interactions | 6.43e-12 | 275 | 15 | 8 | int:DCUN1D1 | |
| Interaction | RBMX interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 7.03e-12 | 461 | 15 | 9 | int:RBMX |
| Interaction | NFX1 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 7.75e-12 | 466 | 15 | 9 | int:NFX1 |
| Interaction | KIF20A interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 HNRNPA1L2 VSIG8 FUS ILF3 HNRNPUL1 HNRNPA3 | 8.39e-12 | 1052 | 15 | 11 | int:KIF20A |
| Interaction | FBXW11 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 8.85e-12 | 473 | 15 | 9 | int:FBXW11 |
| Interaction | SNRPA interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.05e-11 | 482 | 15 | 9 | int:SNRPA |
| Interaction | MCM2 interactions | HNRNPA1 HNRNPA2B1 DDX3Y FAM98A HNRNPA1L2 VSIG8 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.13e-11 | 1081 | 15 | 11 | int:MCM2 |
| Interaction | HNRNPH3 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 HNRNPA1L2 FUS HNRNPUL1 HNRNPA3 | 1.33e-11 | 301 | 15 | 8 | int:HNRNPH3 |
| Interaction | FUS interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.34e-11 | 757 | 15 | 10 | int:FUS |
| Interaction | ACE2 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 HNRNPA1L2 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.44e-11 | 1106 | 15 | 11 | int:ACE2 |
| Interaction | BTRC interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 1.68e-11 | 775 | 15 | 10 | int:BTRC |
| Interaction | HNRNPH2 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 HNRNPA1L2 ILF3 HNRNPUL1 HNRNPA3 | 1.77e-11 | 312 | 15 | 8 | int:HNRNPH2 |
| Interaction | TARDBP interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 FAM98A DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 2.06e-11 | 520 | 15 | 9 | int:TARDBP |
| Interaction | ITFG1 interactions | HNRNPA0 HNRNPA1 HNRNPA2B1 HNRNPH3 DDX3X FUS ILF3 HNRNPUL1 HNRNPA3 | 2.89e-11 | 540 | 15 | 9 | int:ITFG1 |
| Cytoband | Ensembl 112 genes in cytogenetic band chr2q31 | 1.73e-03 | 178 | 16 | 2 | chr2q31 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr12q13 | 9.33e-03 | 423 | 16 | 2 | chr12q13 | |
| GeneFamily | RNA binding motif containing | 2.15e-11 | 213 | 12 | 7 | 725 | |
| GeneFamily | DEAD-box helicases | 3.43e-04 | 42 | 12 | 2 | 499 | |
| GeneFamily | HOXL subclass homeoboxes | 5.26e-04 | 52 | 12 | 2 | 518 | |
| Coexpression | HAY_BONE_MARROW_PRO_B | 1.68e-08 | 304 | 16 | 6 | M39208 | |
| Coexpression | CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN | 6.40e-08 | 669 | 16 | 7 | M18635 | |
| Coexpression | JIANG_MELANOMA_TRM8_CD4 | 1.24e-07 | 426 | 16 | 6 | M48972 | |
| Coexpression | TIEN_INTESTINE_PROBIOTICS_24HR_UP | 6.25e-07 | 561 | 16 | 6 | M1463 | |
| Coexpression | FISCHER_DREAM_TARGETS | 7.89e-07 | 969 | 16 | 7 | M149 | |
| Coexpression | FAN_OVARY_CL1_GPRC5A_TNFRS12A_HIGH_SELECTABLE_FOLLICLE_STROMAL_CELL | 2.39e-06 | 380 | 16 | 5 | M41703 | |
| Coexpression | BENPORATH_SOX2_TARGETS | 2.98e-06 | 734 | 16 | 6 | M3835 | |
| Coexpression | NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_DN | 4.47e-06 | 432 | 16 | 5 | M41149 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_UP | 5.33e-06 | 448 | 16 | 5 | MM1044 | |
| Coexpression | MARTENS_TRETINOIN_RESPONSE_DN | 6.43e-06 | 839 | 16 | 6 | M2099 | |
| Coexpression | TRAVAGLINI_LUNG_BASOPHIL_MAST_2_CELL | 9.36e-06 | 503 | 16 | 5 | M41690 | |
| Coexpression | JIANG_MELANOMA_TRM9_CD8 | 1.16e-05 | 526 | 16 | 5 | M48973 | |
| Coexpression | TRAVAGLINI_LUNG_BRONCHIAL_VESSEL_2_CELL | 1.87e-05 | 272 | 16 | 4 | M41669 | |
| Coexpression | HOUNKPE_HOUSEKEEPING_GENES | 4.01e-05 | 1158 | 16 | 6 | MM1338 | |
| Coexpression | TABULA_MURIS_SENIS_MAMMARY_GLAND_LUMINAL_EPITHELIAL_CELL_OF_MAMMARY_GLAND_AGEING | 5.12e-05 | 352 | 16 | 4 | MM3788 | |
| Coexpression | PUJANA_ATM_PCC_NETWORK | 1.13e-04 | 1394 | 16 | 6 | M9585 | |
| Coexpression | TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C | 1.37e-04 | 454 | 16 | 4 | M19927 | |
| Coexpression | ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_UP | 1.49e-04 | 173 | 16 | 3 | M2480 | |
| Coexpression | BUSSLINGER_GASTRIC_IMMUNE_CELLS | 1.64e-04 | 1492 | 16 | 6 | M40023 | |
| Coexpression | LIU_BREAST_CANCER | 1.71e-04 | 32 | 16 | 2 | M16584 | |
| Coexpression | GSE5099_DAY3_VS_DAY7_MCSF_TREATED_MACROPHAGE_DN | 1.78e-04 | 184 | 16 | 3 | M6593 | |
| Coexpression | GSE16450_CTRL_VS_IFNA_12H_STIM_IMMATURE_NEURON_CELL_LINE_UP | 2.18e-04 | 197 | 16 | 3 | M7403 | |
| Coexpression | GSE16386_IL4_VS_IL4_AND_ROSIGLITAZONE_STIM_MACROPHAGE_6H_UP | 2.24e-04 | 199 | 16 | 3 | M8000 | |
| Coexpression | GSE24574_NAIVE_VS_TCONV_CD4_TCELL_DN | 2.28e-04 | 200 | 16 | 3 | M8330 | |
| Coexpression | GSE9006_TYPE_1_DIABETES_AT_DX_VS_4MONTH_POST_DX_PBMC_UP | 2.28e-04 | 200 | 16 | 3 | M5787 | |
| Coexpression | GSE9006_TYPE_1_DIABETES_AT_DX_VS_1MONTH_POST_DX_PBMC_UP | 2.28e-04 | 200 | 16 | 3 | M5783 | |
| Coexpression | GSE9006_HEALTHY_VS_TYPE_1_DIABETES_PBMC_1MONTH_POST_DX_UP | 2.28e-04 | 200 | 16 | 3 | M5777 | |
| Coexpression | GSE9006_HEALTHY_VS_TYPE_1_DIABETES_PBMC_4MONTH_POST_DX_UP | 2.28e-04 | 200 | 16 | 3 | M5779 | |
| Coexpression | HALLMARK_MYC_TARGETS_V1 | 2.28e-04 | 200 | 16 | 3 | M5926 | |
| Coexpression | BENPORATH_NANOG_TARGETS | 2.32e-04 | 988 | 16 | 5 | M6616 | |
| Coexpression | PAL_PRMT5_TARGETS_UP | 2.63e-04 | 210 | 16 | 3 | MM1172 | |
| Coexpression | MARTORIATI_MDM4_TARGETS_FETAL_LIVER_DN | 2.72e-04 | 543 | 16 | 4 | MM997 | |
| Coexpression | TABULA_MURIS_SENIS_MAMMARY_GLAND_T_CELL_AGEING | 2.76e-04 | 545 | 16 | 4 | MM3785 | |
| Coexpression | TABULA_MURIS_SENIS_SPLEEN_GRANULOCYTE_AGEING | 3.18e-04 | 224 | 16 | 3 | MM3836 | |
| Coexpression | OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP | 3.18e-04 | 224 | 16 | 3 | M12383 | |
| Coexpression | ONO_FOXP3_TARGETS_DN | 3.41e-04 | 45 | 16 | 2 | MM1271 | |
| Coexpression | HOUNKPE_HOUSEKEEPING_GENES | 4.31e-04 | 1129 | 16 | 5 | M42508 | |
| Coexpression | JOHANSSON_GLIOMAGENESIS_BY_PDGFB_UP | 6.06e-04 | 60 | 16 | 2 | MM1101 | |
| Coexpression | SCHLOSSER_SERUM_RESPONSE_DN | 7.30e-04 | 705 | 16 | 4 | M1410 | |
| Coexpression | ZHANG_UTERUS_C1_REGENERATIVE_UP | 7.59e-04 | 302 | 16 | 3 | MM16604 | |
| Coexpression | BUSSLINGER_DUODENAL_DIFFERENTIATING_STEM_CELLS | 7.81e-04 | 305 | 16 | 3 | M40025 | |
| Coexpression | TRAVAGLINI_LUNG_OLR1_CLASSICAL_MONOCYTE_CELL | 8.06e-04 | 724 | 16 | 4 | M41700 | |
| Coexpression | BUSSLINGER_ESOPHAGEAL_PROLIFERATING_BASAL_CELLS | 8.24e-04 | 70 | 16 | 2 | M40002 | |
| Coexpression | LIN_APC_TARGETS | 8.47e-04 | 71 | 16 | 2 | M17434 | |
| Coexpression | TABULA_MURIS_SENIS_LARGE_INTESTINE_SECRETORY_CELL_AGEING | 8.48e-04 | 734 | 16 | 4 | MM3740 | |
| Coexpression | TABULA_MURIS_SENIS_MAMMARY_GLAND_B_CELL_AGEING | 8.57e-04 | 315 | 16 | 3 | MM3784 | |
| Coexpression | YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_7 | 8.95e-04 | 73 | 16 | 2 | M17481 | |
| Coexpression | BILANGES_RAPAMYCIN_SENSITIVE_VIA_TSC1_AND_TSC2 | 9.45e-04 | 75 | 16 | 2 | MM1306 | |
| Coexpression | BUSSLINGER_ESOPHAGEAL_EARLY_SUPRABASAL_CELLS | 1.05e-03 | 79 | 16 | 2 | M40003 | |
| Coexpression | FALVELLA_SMOKERS_WITH_LUNG_CANCER | 1.10e-03 | 81 | 16 | 2 | M18536 | |
| Coexpression | HE_LIM_SUN_FETAL_LUNG_C0_EARLY_FIBROBLAST | 1.10e-03 | 81 | 16 | 2 | M45667 | |
| Coexpression | ZHANG_UTERUS_C7_EPITHELIAL2_CELL | 1.16e-03 | 799 | 16 | 4 | MM16613 | |
| Coexpression | YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_7 | 1.18e-03 | 84 | 16 | 2 | MM873 | |
| Coexpression | MENON_FETAL_KIDNEY_0_CAP_MESENCHYME_CELLS | 1.36e-03 | 90 | 16 | 2 | M39250 | |
| Coexpression | TRAVAGLINI_LUNG_PROLIFERATING_BASAL_CELL | 1.74e-03 | 891 | 16 | 4 | M41654 | |
| Coexpression | SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP | 1.75e-03 | 404 | 16 | 3 | M19488 | |
| Coexpression | JIANG_MELANOMA_TRM3_CD8 | 2.01e-03 | 424 | 16 | 3 | M48967 | |
| Coexpression | WOOD_EBV_EBNA1_TARGETS_UP | 2.02e-03 | 110 | 16 | 2 | M1696 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_UP | 2.15e-03 | 434 | 16 | 3 | M15150 | |
| Coexpression | BAELDE_DIABETIC_NEPHROPATHY_DN | 2.19e-03 | 437 | 16 | 3 | M4665 | |
| Coexpression | HAHTOLA_MYCOSIS_FUNGOIDES_CD4_DN | 2.20e-03 | 115 | 16 | 2 | M19849 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Floor Plate_top-relative-expression-ranked_2500_k-means-cluster#2 | 1.02e-04 | 395 | 14 | 4 | Facebase_RNAseq_e8.5_Floor Plate_2500_K2 | |
| ToppCell | COVID-19|World / Disease, condition lineage and cell class | 6.93e-09 | 200 | 16 | 5 | 7dec470c379cd89f05a0f37c8628b21f136e52f0 | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_B-B_lineage-pre_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.10e-07 | 196 | 16 | 4 | 6ba02b806d440eed45bad7616bf3b8be57034427 | |
| ToppCell | Control-Classical_Monocyte-cMono_2|Classical_Monocyte / Disease condition and Cell class | 6.23e-07 | 197 | 16 | 4 | eb7610c9496a95a5fd866e16abcbc39b83abe617 | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B-B_lineage|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.23e-07 | 197 | 16 | 4 | 7290f05d0b8465637420119941bcbf2fae44a7e4 | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B-B_lineage-pre_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.23e-07 | 197 | 16 | 4 | 78122e1fb80e0ac3084dd4f7c551996330a701df | |
| ToppCell | facs-Diaphragm-Limb_Muscle-3m|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.23e-07 | 197 | 16 | 4 | b0e2ea81308bce289cb7cbea0e27de1d01afeed2 | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.23e-07 | 197 | 16 | 4 | 31dfd9842410b5c629f39b5130233995dceb0aef | |
| ToppCell | 10x_3'_v3|World / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 6.35e-07 | 198 | 16 | 4 | aabb8e9b162ae4cb26ea860c99decdbb51e379e1 | |
| ToppCell | 390C-Lymphocytic-NK_cells-NK_cell_A|NK_cells / Donor, Lineage, Cell class and subclass (all cells) | 6.35e-07 | 198 | 16 | 4 | a1c8e5c332336823c47c04e56b6d7bc8f057c9da | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_B|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.48e-07 | 199 | 16 | 4 | 713dfd8552635645db5e0b5721c64e5c9b4aa06c | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_B-B_lineage|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.48e-07 | 199 | 16 | 4 | ea75804c34989c99aab542e6d72617ed144819b6 | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.48e-07 | 199 | 16 | 4 | 5478b78349b5d8d57f30bb650dcbd5fdb84283d6 | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.48e-07 | 199 | 16 | 4 | 8e7f9312dec1e3a92b6a0ccc7baa2d46e89c11f3 | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_B-B_lineage|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.48e-07 | 199 | 16 | 4 | fe3b7d540a644dfc6beea171c809b4d1ba4e188f | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.48e-07 | 199 | 16 | 4 | 8daf945fc93169b0a4fa3ef9f4a87eedd52e314a | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_B|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.48e-07 | 199 | 16 | 4 | cdee798e3586e4e7a15de598239090a85752ea1e | |
| ToppCell | 10x5'v1-week_17-19-Lymphocytic_B-B_lineage-pre_B_progenitor|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 6.48e-07 | 199 | 16 | 4 | be425e9cb90a73289026b1b7cb581e1c02a8985e | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_B-B_lineage-pre_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.48e-07 | 199 | 16 | 4 | dadee9fc6ce4f4bdb19d29326889316443dda0cb | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_B-B_lineage|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.61e-07 | 200 | 16 | 4 | 0fd9a8730b7dc461ddf4586899d363541e72d8ba | |
| ToppCell | 5'-GW_trimst-1-SmallIntestine-Mesenchymal-immature_mesenchymal_cell|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.61e-07 | 200 | 16 | 4 | 4234bdc70a9941d4bf77148d75bd271e0c114b88 | |
| ToppCell | TCGA-Bile_Duct-Primary_Tumor-Cholangiocarcinoma|TCGA-Bile_Duct / Sample_Type by Project: Shred V9 | 6.61e-07 | 200 | 16 | 4 | ad2a6da0b1ae7a9212a3c91e5eec4baa7481d8dc | |
| ToppCell | TCGA-Bile_Duct-Primary_Tumor|TCGA-Bile_Duct / Sample_Type by Project: Shred V9 | 6.61e-07 | 200 | 16 | 4 | 0350e5ffd36033099b7e32a1fdd790fff99790dc | |
| ToppCell | 10x5'v1-week_17-19-Lymphocytic_B-B_lineage|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 6.61e-07 | 200 | 16 | 4 | c28d4ca51d2e2a3a22784ee251975f16a55b0297 | |
| ToppCell | mild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 6.61e-07 | 200 | 16 | 4 | 12f1685ce8f218433068e090c9d839cd5a1910bf | |
| ToppCell | Sepsis-Bac-SEP|Sepsis / Disease, condition lineage and cell class | 6.61e-07 | 200 | 16 | 4 | 1f80e6a49c632b3ba0cdac1225c78e5d6d6d78a5 | |
| ToppCell | 10x5'v1-week_17-19-Lymphocytic_B|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 6.61e-07 | 200 | 16 | 4 | 364f09eb9ae4913f5c80a29e943e1c0b2ffd5f93 | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_B|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.61e-07 | 200 | 16 | 4 | 19a4213f180ac2d29625d140b602a93a74ab3fdd | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_2|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.47e-05 | 136 | 16 | 3 | 3e13dc0634f3b05e9f9e6c3193f843f62e603b78 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_2-Sox4|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.47e-05 | 136 | 16 | 3 | 0185486c39700dd2f72d79be6d283494dd8379c9 | |
| ToppCell | E16.5-samps|World / Age Group, Lineage, Cell class and subclass | 1.93e-05 | 149 | 16 | 3 | e94d075f68c1c70c89fab50b1b765b5dda650d09 | |
| ToppCell | TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Colon_Adenocarcinoma-4|TCGA-Colorectal / Sample_Type by Project: Shred V9 | 2.67e-05 | 166 | 16 | 3 | 52293b8a74d46e6161fb6a2e7e86e51fd9e89a5b | |
| ToppCell | 3'_v3-lymph-node_spleen|World / Manually curated celltypes from each tissue | 2.91e-05 | 171 | 16 | 3 | 7aae88da5b37c20f10118325a048f08906be994c | |
| ToppCell | 3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-CD8-positive,_alpha-beta_T_cell-CD8_T_cells-CD8_T_cells_L.1.1.0.4|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.17e-05 | 176 | 16 | 3 | ce85a13e10cf37f5cf38ca8b0bac6701b6d00ffd | |
| ToppCell | facs-Heart-RA-18m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.28e-05 | 178 | 16 | 3 | b505e2550860e777535ee95f29c936242fd607f1 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(15)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 3.39e-05 | 180 | 16 | 3 | ed4966765a6b25456f68185cf0648c4a3a21d7fe | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 3.39e-05 | 180 | 16 | 3 | 44988c34861df359a68376500c42a64fbcc4b431 | |
| ToppCell | 10x5'-Liver-Lymphocytic_T_CD4-T_CD4/CD8|Liver / Manually curated celltypes from each tissue | 3.45e-05 | 181 | 16 | 3 | f2315414e714ac86211546a935660c4be6e85f1b | |
| ToppCell | Smart-start-Cell-Wel_seq-Neoplastic-Stem-like-NPC-like-NPC-like_Prolif-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.51e-05 | 182 | 16 | 3 | f549b986caebc5eb1b2d12f34fe33087e8324a31 | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8|GI_small-bowel / Manually curated celltypes from each tissue | 3.86e-05 | 188 | 16 | 3 | ab9b725d6e0cdab8e9ddda6dee09e14730e9a578 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.92e-05 | 189 | 16 | 3 | 0e8d1be3c406d1a393e18faccfe89116a8f82bcf | |
| ToppCell | facs-BAT-Fat-3m|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.92e-05 | 189 | 16 | 3 | 7ce71f9c81512ed38c804f025908746b4af3aab1 | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-21m-Epithelial|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.92e-05 | 189 | 16 | 3 | 965e0e388251e7318f8b463816dc96ccb4658677 | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8|lymph-node_spleen / Manually curated celltypes from each tissue | 4.11e-05 | 192 | 16 | 3 | 47646d7e4990be85072987f92bf18d52f8da752e | |
| ToppCell | PBMC-Control-cDC_6|Control / Compartment, Disease Groups and Clusters | 4.11e-05 | 192 | 16 | 3 | 41a7201febb7d88a39e4ee64df04cce18c691df8 | |
| ToppCell | 10x3'2.3|World / cell types per 3 fetal stages;per 3',per 5' | 4.24e-05 | 194 | 16 | 3 | fc7ed8350ffe1475b8934dfbb107b51991876b0b | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_B-B_lineage-pro_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 4.24e-05 | 194 | 16 | 3 | f64da5f62e29253d60b9546edf734ba5c17daae1 | |
| ToppCell | E12.5|World / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 4.24e-05 | 194 | 16 | 3 | 4b335e4da58de1cd94194dc4208ce83854e5e50a | |
| ToppCell | droplet-Marrow-BM-1m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.31e-05 | 195 | 16 | 3 | 637b06ef3967b03f7165d102d316e8b7161a817d | |
| ToppCell | mild_COVID-19|World / disease group, cell group and cell class (v2) | 4.31e-05 | 195 | 16 | 3 | 6dbe9db5f0e94f2e91b3d1282855d200051ab0ba | |
| ToppCell | Megakaryocytic-erythropoietic-MEP|Megakaryocytic-erythropoietic / Lineage, cell class and subclass | 4.37e-05 | 196 | 16 | 3 | f90e7fe3a7b2fff30d01a25cc500876861c2e4f1 | |
| ToppCell | Megakaryocytic-erythropoietic-MEP-MEP|Megakaryocytic-erythropoietic / Lineage, cell class and subclass | 4.37e-05 | 196 | 16 | 3 | 4e97010185fa9392da8f69e7b2a7395bf063f8ff | |
| ToppCell | COVID-19_Mild|World / Disease group, lineage and cell class | 4.44e-05 | 197 | 16 | 3 | 5c33454b10023decd2f5ccda9229b6512659711e | |
| ToppCell | 10x3'2.3-week_17-19|World / cell types per 3 fetal stages;per 3',per 5' | 4.44e-05 | 197 | 16 | 3 | f5cfad0b42d0f817e22cc78b9bfb2b4b7e4330ed | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_B-B_lineage-pre_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 4.44e-05 | 197 | 16 | 3 | 106b0f9a0425facc634feb7498c9ba2c55edfbf8 | |
| ToppCell | 3'-GW_trimst-2-LargeIntestine-Mesenchymal-immature_mesenchymal_cell|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.44e-05 | 197 | 16 | 3 | 9af431323da6d099459b7360af40e5df998cffbd | |
| ToppCell | 3'-GW_trimst-1-LargeIntestine-Mesenchymal|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.44e-05 | 197 | 16 | 3 | c7b33d64e5cba3a8fc6f2d6aa85ebc83893195de | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 4.51e-05 | 198 | 16 | 3 | 8aa4149d2c1cec73cfd654db093252ec8ec5ef68 | |
| ToppCell | wk_15-18-Mesenchymal-Fibroblast-Early_fibro|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 4.51e-05 | 198 | 16 | 3 | ecf0a8f2e07f336e23b6f32a2c48d3c7eb66572b | |
| ToppCell | 3'-GW_trimst-1-LargeIntestine|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.51e-05 | 198 | 16 | 3 | ea6621a148a96c8ffa1a93a35c9e288545d2637a | |
| ToppCell | PBMC-Mild|PBMC / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.51e-05 | 198 | 16 | 3 | 44417089b62056269cac38d3134ff209c05b7007 | |
| ToppCell | systemic_lupus_erythematosus-treated|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.51e-05 | 198 | 16 | 3 | 8165ff735095c52994fb5057d89be93cc378b7da | |
| ToppCell | systemic_lupus_erythematosus-flare|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.51e-05 | 198 | 16 | 3 | 4c93ee921d56132d80832d8e94563f32ccf13bbc | |
| ToppCell | PBMC-Mild|PBMC / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.51e-05 | 198 | 16 | 3 | 28ef3fc4c17dcb765537b75917f7db78baa522db | |
| ToppCell | 10x_3'_v2v3-Neoplastic-Stem-like-OPC-like-OPC-like_Prolif-F|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 4.51e-05 | 198 | 16 | 3 | cd876fba12ff30b74aa507286cb1f3a867011a92 | |
| ToppCell | (2)_MNPs-(2)_Dendritic_Cells|(2)_MNPs / Oesophagus cell shreds on cell class (v1) and cell subclass (v1) | 4.51e-05 | 198 | 16 | 3 | 4c1f155298b7d0afddfeb2744b369a1ffd823916 | |
| ToppCell | wk_08-11-Mesenchymal-Fibroblast-Early_fibro|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 4.57e-05 | 199 | 16 | 3 | d67f5ae05daf942fb79f5b962021f37f4e275f4d | |
| ToppCell | 3'-GW_trimst-1|3' / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.57e-05 | 199 | 16 | 3 | ecfb6381e2971a3e355e661a6df0021914485e74 | |
| ToppCell | Enterocyte_Progenitors|World / shred on cell type and cluster | 4.57e-05 | 199 | 16 | 3 | 776bcc887927dea9ebd76ec4338ce2225c319c2c | |
| ToppCell | lymphoid|World / Lineage, cell class and subclass | 4.57e-05 | 199 | 16 | 3 | bf599721e7109cf9f361e9381544c291920c28be | |
| ToppCell | Healthy/Control|World / Disease group and Cell class | 4.57e-05 | 199 | 16 | 3 | 2623c42b3e79e401a485879b52e8bbcbc581544d | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 4.57e-05 | 199 | 16 | 3 | 99778178e3ec121802db938db8c5475d19b43fec | |
| ToppCell | 3'-GW_trimst-2-LargeIntestine-Mesenchymal|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.57e-05 | 199 | 16 | 3 | c007cd51577e31553395ceaed70ad447e5854546 | |
| ToppCell | lymphoid-T_cell-CD8+_Naive_T_cell|T_cell / Lineage, cell class and subclass | 4.57e-05 | 199 | 16 | 3 | 9ee40563e840a7fe97e7592539d42e19db438c64 | |
| ToppCell | Smart-start-Cell-Wel_seq-Neoplastic-Stem-like|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 4.57e-05 | 199 | 16 | 3 | 59915b6db86fd0cc83a0bf9a3a1dda08522ec8d3 | |
| ToppCell | severe|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 4.64e-05 | 200 | 16 | 3 | accc618d6b960bff30cb531c1226295bfc8650f6 | |
| ToppCell | COVID-19-COVID-19_Mild|COVID-19 / Disease, condition lineage and cell class | 4.64e-05 | 200 | 16 | 3 | 62c25042086f1afd1102e0720e933c2e476468fd | |
| ToppCell | Bac-SEP|World / Disease, Lineage and Cell Type | 4.64e-05 | 200 | 16 | 3 | fa4e027b304c3460489992b84ad81d355a5b55ea | |
| ToppCell | wk_08-11|World / Celltypes from embryonic and fetal-stage human lung | 4.64e-05 | 200 | 16 | 3 | aa35c33762880a5e030a7e691c425524f7dbff8a | |
| ToppCell | TCGA-Ovary-Primary_Tumor|TCGA-Ovary / Sample_Type by Project: Shred V9 | 6.46e-04 | 106 | 16 | 2 | 14f548be39cec604fbdae0382cbf434fa4049840 | |
| ToppCell | TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma|TCGA-Ovary / Sample_Type by Project: Shred V9 | 6.46e-04 | 106 | 16 | 2 | 939b80950d39cdc7149a05fdfb64c8810064cdb1 | |
| ToppCell | TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma|TCGA-Ovary / Sample_Type by Project: Shred V9 | 6.46e-04 | 106 | 16 | 2 | e9e1b55f32b3d5b9eeec94a997912e5c21c1fb48 | |
| ToppCell | Smart-start-Cell-Wel_seq-Neoplastic-Stem-like-OPC-like-OPC-like_Prolif|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.19e-03 | 144 | 16 | 2 | 81a18478bc7284b903a4cad67b9049576a8c2b72 | |
| ToppCell | 343B-Lymphocytic-CD4_T-cell-CD4+_Naive_T_cell_/_CD4+_Trm_cell|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 1.23e-03 | 147 | 16 | 2 | d655e6ede8bca65a62efada2b15c7916e5f19324 | |
| ToppCell | facs-MAT-Fat-24m|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.39e-03 | 156 | 16 | 2 | 7433c6d4eb4d061844d8979c1e648d8ed56e1073 | |
| ToppCell | PND01-03-samps-Endothelial-Postnatal_endothelial-endothelial_cells_C|PND01-03-samps / Age Group, Lineage, Cell class and subclass | 1.39e-03 | 156 | 16 | 2 | 6c8f442ed94ae31e6832b68137e98ae78091ac6c | |
| ToppCell | PBMC-Mild-cDC_3|Mild / Compartment, Disease Groups and Clusters | 1.42e-03 | 158 | 16 | 2 | 5fefab4831687cd8dd45f5cc84f681398069c3be | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_low-phase|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.51e-03 | 163 | 16 | 2 | 2d6fd2562d78be9f83fa35d811eb7e27eb8cc5d1 | |
| ToppCell | (07)_Ionocytes-(2)_GFP_FOXI1|(07)_Ionocytes / shred by cell type by condition | 1.68e-03 | 172 | 16 | 2 | 5776b638b845d054f6e884e7df0412477f48517d | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(15)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 1.68e-03 | 172 | 16 | 2 | 7f3d0ef18f5df1ed80498d435b0378ca398c0b88 | |
| ToppCell | NS-critical-d_16-33-Epithelial-unknown_epithelial|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.68e-03 | 172 | 16 | 2 | c0b5e4889aef2f168d9f6db19a63b24bfd249316 | |
| ToppCell | PBMC-Convalescent|PBMC / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.74e-03 | 175 | 16 | 2 | d3f897271b64872535213a3dc27b9330255ef9ee | |
| ToppCell | droplet-Tongue-nan-24m|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.76e-03 | 176 | 16 | 2 | 9739b0653c511ab017507a0c7ee4f6d7082e87db | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_T-T4_naive-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 1.78e-03 | 177 | 16 | 2 | db6de487ef7976b444afadbf3ac60b3259925566 | |
| ToppCell | normal-na-Lymphocytic_T-CD4-positive,_alpha-beta_T_cell-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 1.80e-03 | 178 | 16 | 2 | fa3585383a1e7da460c88a802aaa81246d681b6b | |
| ToppCell | 3'_v3|World / Manually curated celltypes from each tissue | 1.80e-03 | 178 | 16 | 2 | 42502f14d9c756df8104900ac6484477b885d3d9 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(15)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 1.82e-03 | 179 | 16 | 2 | 6718cadcc2d3b64717ed84244ef1242d392662dc | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Neuronal-ventral_progenitors_and_neurons_2|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type. | 1.82e-03 | 179 | 16 | 2 | d95367d689732ab2653e8d70d8d8e5eb15ae6eef | |
| ToppCell | C_00|World / shred on cell type and cluster | 1.82e-03 | 179 | 16 | 2 | da2dadc3266ffebd4a34ac61bfa05fddcadcde4c | |
| ToppCell | BLOOD-unannotated|BLOOD / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 1.86e-03 | 181 | 16 | 2 | 3a5c0c701fc2c078e1504bbf88ae708546cc74a3 | |
| ToppCell | Leuk-UTI-Lymphocyte-T_NK-CD8_Naive|Leuk-UTI / Disease, Lineage and Cell Type | 1.88e-03 | 182 | 16 | 2 | 3500a826d86beb98980e2b24e074b02e8e2f957e | |
| Computational | Genes in the cancer module 32. | 5.02e-08 | 241 | 11 | 6 | MODULE_32 | |
| Computational | Neighborhood of FBL | 1.51e-07 | 140 | 11 | 5 | MORF_FBL | |
| Computational | RNA splicing. | 3.89e-07 | 65 | 11 | 4 | MODULE_183 | |
| Computational | Neighborhood of UBE2I | 2.11e-06 | 238 | 11 | 5 | MORF_UBE2I | |
| Computational | Neighborhood of DEK | 3.52e-06 | 264 | 11 | 5 | MORF_DEK | |
| Computational | Neighborhood of DENR | 1.62e-05 | 51 | 11 | 3 | GNF2_DENR | |
| Computational | Neighborhood of ANP32B | 3.33e-05 | 198 | 11 | 4 | MORF_ANP32B | |
| Computational | Neighborhood of DDX5 | 3.36e-05 | 65 | 11 | 3 | GCM_DDX5 | |
| Computational | Neighborhood of RBBP6 | 4.20e-05 | 70 | 11 | 3 | GNF2_RBBP6 | |
| Computational | Neighborhood of ACP1 | 4.27e-05 | 211 | 11 | 4 | MORF_ACP1 | |
| Computational | Neighborhood of HDAC1 | 8.82e-05 | 254 | 11 | 4 | MORF_HDAC1 | |
| Computational | Neighborhood of BUB3 | 1.23e-04 | 277 | 11 | 4 | MORF_BUB3 | |
| Computational | Neighborhood of CSNK2B | 1.42e-04 | 287 | 11 | 4 | MORF_CSNK2B | |
| Computational | Neighborhood of GNB1 | 1.79e-04 | 305 | 11 | 4 | MORF_GNB1 | |
| Computational | Neighborhood of RAD23A | 2.97e-04 | 348 | 11 | 4 | MORF_RAD23A | |
| Computational | Genes in the cancer module 14. | 3.28e-04 | 357 | 11 | 4 | MODULE_15 | |
| Computational | Genes in the cancer module 98. | 4.73e-04 | 393 | 11 | 4 | MODULE_98 | |
| Computational | Neighborhood of G22P1 | 6.04e-04 | 172 | 11 | 3 | MORF_G22P1 | |
| Computational | Neighborhood of HAT1 | 6.36e-04 | 175 | 11 | 3 | MORF_HAT1 | |
| Computational | Neighborhood of RAF1 | 8.40e-04 | 43 | 11 | 2 | GCM_RAF1 | |
| Computational | Neighborhood of XRCC5 | 1.49e-03 | 235 | 11 | 3 | MORF_XRCC5 | |
| Computational | Neighborhood of ESPL1 | 1.69e-03 | 61 | 11 | 2 | MORF_ESPL1 | |
| Computational | Neighborhood of EIF3S2 | 1.71e-03 | 246 | 11 | 3 | MORF_EIF3S2 | |
| Computational | Neighborhood of SART1 | 1.80e-03 | 63 | 11 | 2 | MORF_SART1 | |
| Computational | Neighborhood of TERF1 | 2.03e-03 | 67 | 11 | 2 | MORF_TERF1 | |
| Computational | Neighborhood of RAN | 2.18e-03 | 268 | 11 | 3 | MORF_RAN | |
| Computational | Neighborhood of NPM1 | 2.34e-03 | 72 | 11 | 2 | GNF2_NPM1 | |
| Computational | Neighborhood of CDK2 | 2.34e-03 | 72 | 11 | 2 | MORF_CDK2 | |
| Computational | Neighborhood of SOD1 | 2.42e-03 | 278 | 11 | 3 | MORF_SOD1 | |
| Computational | Neighborhood of HDAC2 | 2.47e-03 | 280 | 11 | 3 | MORF_HDAC2 | |
| Computational | Genes in the cancer module 198. | 3.09e-03 | 303 | 11 | 3 | MODULE_198 | |
| Computational | Neighborhood of PCNA | 3.10e-03 | 83 | 11 | 2 | MORF_PCNA | |
| Computational | Neighborhood of CCNI | 3.47e-03 | 88 | 11 | 2 | MORF_CCNI | |
| Computational | Neighborhood of APEX1 | 3.79e-03 | 92 | 11 | 2 | GNF2_APEX1 | |
| Computational | Neighborhood of UBE2N | 4.04e-03 | 95 | 11 | 2 | MORF_UBE2N | |
| Computational | Transcription. | 4.12e-03 | 96 | 11 | 2 | MODULE_124 | |
| Computational | Neighborhood of CSNK2B | 4.38e-03 | 99 | 11 | 2 | GCM_CSNK2B | |
| Computational | Genes in the cancer module 3. | 6.03e-03 | 384 | 11 | 3 | MODULE_3 | |
| Computational | Neighborhood of DNMT1 | 6.16e-03 | 118 | 11 | 2 | MORF_DNMT1 | |
| Computational | Neighborhood of EIF3S6 | 6.57e-03 | 122 | 11 | 2 | MORF_EIF3S6 | |
| Computational | Neighborhood of ACTG1 | 6.78e-03 | 124 | 11 | 2 | GCM_ACTG1 | |
| Computational | Neighborhood of PPP2CA | 7.32e-03 | 129 | 11 | 2 | MORF_PPP2CA | |
| Computational | Neighborhood of AP3D1 | 7.43e-03 | 130 | 11 | 2 | MORF_AP3D1 | |
| Computational | Neighborhood of EIF4A2 | 8.34e-03 | 138 | 11 | 2 | MORF_EIF4A2 | |
| Computational | Neighborhood of FBL | 9.30e-03 | 146 | 11 | 2 | GNF2_FBL | |
| Computational | Neighborhood of CDC10 | 9.30e-03 | 146 | 11 | 2 | MORF_CDC10 | |
| Computational | Neighborhood of MYST2 | 1.27e-02 | 172 | 11 | 2 | GCM_MYST2 | |
| Drug | AC1L1AUZ | 4.15e-08 | 157 | 15 | 5 | CID000001160 | |
| Drug | AC1NRA5C | 6.95e-08 | 174 | 15 | 5 | CID005287709 | |
| Drug | Iohexol [66108-95-0]; Down 200; 4.8uM; HL60; HT_HG-U133A | 1.02e-07 | 188 | 15 | 5 | 2461_DN | |
| Drug | bromovanin | 1.20e-06 | 127 | 15 | 4 | ctd:C515564 | |
| Drug | SK&F 83959 | 2.53e-06 | 153 | 15 | 4 | ctd:C080703 | |
| Drug | Metoclopramide monohydrochloride [7232-21-5]; Down 200; 11.8uM; HL60; HT_HG-U133A | 5.49e-06 | 186 | 15 | 4 | 2353_DN | |
| Drug | R(+)-verapamil hydrochloride; Down 200; 10uM; MCF7; HG-U133A | 6.89e-06 | 197 | 15 | 4 | 164_DN | |
| Drug | AC1L1B55 | 7.85e-06 | 454 | 15 | 5 | CID000001287 | |
| Drug | genistein | 4.70e-05 | 1117 | 15 | 6 | CID005280961 | |
| Drug | pentabromodiphenyl ether | 9.46e-05 | 1266 | 15 | 6 | ctd:C086401 | |
| Drug | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1.54e-04 | 163 | 15 | 3 | ctd:D015647 | |
| Drug | Cephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; MCF7; HT_HG-U133A | 1.77e-04 | 171 | 15 | 3 | 5247_DN | |
| Drug | Emetine dihydrochloride [316-42-7]; Down 200; 7.2uM; MCF7; HT_HG-U133A | 1.80e-04 | 172 | 15 | 3 | 2801_DN | |
| Drug | Cephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; MCF7; HT_HG-U133A | 1.93e-04 | 176 | 15 | 3 | 5612_DN | |
| Drug | Emetine dihydrochloride [316-42-7]; Down 200; 7.2uM; MCF7; HT_HG-U133A | 1.96e-04 | 177 | 15 | 3 | 4827_DN | |
| Drug | Cephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; PC3; HT_HG-U133A | 2.03e-04 | 179 | 15 | 3 | 4651_DN | |
| Drug | Cephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; MCF7; HT_HG-U133A | 2.06e-04 | 180 | 15 | 3 | 3290_DN | |
| Drug | Parthenolide [20554-84-1]; Down 200; 16.2uM; MCF7; HT_HG-U133A | 2.16e-04 | 183 | 15 | 3 | 5530_DN | |
| Drug | Emetine dihydrochloride [316-42-7]; Down 200; 7.2uM; PC3; HT_HG-U133A | 2.16e-04 | 183 | 15 | 3 | 4243_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 2.31e-04 | 187 | 15 | 3 | 4302_DN | |
| Drug | Niclosamide [50-65-7]; Down 200; 12.2uM; HL60; HG-U133A | 2.34e-04 | 188 | 15 | 3 | 1998_DN | |
| Drug | Adana | 2.52e-04 | 36 | 15 | 2 | CID000117765 | |
| Drug | Clobetasol propionate [25122-46-7]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 2.53e-04 | 193 | 15 | 3 | 6835_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.57e-04 | 194 | 15 | 3 | 5017_DN | |
| Drug | 0297417-0002B [362658-29-5]; Down 200; 10uM; MCF7; HT_HG-U133A | 2.65e-04 | 196 | 15 | 3 | 6902_DN | |
| Drug | Acetopromazine maleate salt [3598-37-6]; Down 200; 9uM; HL60; HG-U133A | 2.69e-04 | 197 | 15 | 3 | 1777_DN | |
| Drug | Trifluoperazine dihydrochloride [440-17-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A | 2.73e-04 | 198 | 15 | 3 | 7420_DN | |
| Drug | Coralyne chloride hydrate [38989-38-7]; Down 200; 9.6uM; HL60; HT_HG-U133A | 2.73e-04 | 198 | 15 | 3 | 1298_DN | |
| Drug | Chlorpropamide [94-20-2]; Down 200; 14.4uM; HL60; HG-U133A | 2.81e-04 | 200 | 15 | 3 | 1594_DN | |
| Drug | pelargonic acid | 5.07e-04 | 51 | 15 | 2 | ctd:C008776 | |
| Drug | Buspirone | 5.92e-04 | 622 | 15 | 4 | ctd:D002065 | |
| Drug | butylidenephthalide | 6.78e-04 | 59 | 15 | 2 | ctd:C026105 | |
| Drug | RG-2 | 7.49e-04 | 62 | 15 | 2 | CID003070537 | |
| Disease | myopathy (implicated_via_orthology) | 2.73e-11 | 48 | 15 | 5 | DOID:423 (implicated_via_orthology) | |
| Disease | neurodegenerative disease (implicated_via_orthology) | 7.72e-09 | 145 | 15 | 5 | DOID:1289 (implicated_via_orthology) | |
| Disease | childhood medulloblastoma (implicated_via_orthology) | 2.41e-07 | 2 | 15 | 2 | DOID:3869 (implicated_via_orthology) | |
| Disease | Inclusion body myopathy with Paget disease of bone and frontotemporal dementia | 7.23e-07 | 3 | 15 | 2 | cv:C1833662 | |
| Disease | INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE AND FRONTOTEMPORAL DEMENTIA | 7.23e-07 | 3 | 15 | 2 | C1833662 | |
| Disease | Sertoli cell-only syndrome (implicated_via_orthology) | 1.45e-06 | 4 | 15 | 2 | DOID:0050457 (implicated_via_orthology) | |
| Disease | Amyotrophic Lateral Sclerosis | 3.22e-06 | 58 | 15 | 3 | C0002736 | |
| Disease | autosomal dominant limb-girdle muscular dystrophy type 3 (implicated_via_orthology) | 3.61e-06 | 6 | 15 | 2 | DOID:0110306 (implicated_via_orthology) | |
| Disease | hepatocellular carcinoma (is_marker_for) | 4.37e-04 | 301 | 15 | 3 | DOID:684 (is_marker_for) | |
| Disease | lung non-small cell carcinoma (is_marker_for) | 3.26e-03 | 169 | 15 | 2 | DOID:3908 (is_marker_for) | |
| Disease | Alzheimer's disease (is_marker_for) | 7.36e-03 | 257 | 15 | 2 | DOID:10652 (is_marker_for) | |
| Disease | white matter microstructure measurement | 1.63e-02 | 390 | 15 | 2 | EFO_0005674 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| SCGGGGYGGSGDGYN | 231 | Q32P51 | |
| GYGGSGDGYNGFGND | 236 | Q32P51 | |
| GDGYNGFGNDGSNFG | 241 | Q32P51 | |
| GFGNDGSNFGGGGSY | 246 | Q32P51 | |
| GSNFGGGGSYNDFGN | 251 | Q32P51 | |
| SRGGGGYGGSGDGYN | 186 | A0A2R8Y4L2 | |
| GYGGSGDGYNGFGND | 191 | A0A2R8Y4L2 | |
| GDGYNGFGNDGSNFG | 196 | A0A2R8Y4L2 | |
| GFGNDGSNFGGGGSY | 201 | A0A2R8Y4L2 | |
| GSNFGGGGSYNDFGN | 206 | A0A2R8Y4L2 | |
| SRGFGGGGYGGFYNS | 631 | O00571 | |
| GGGYGGFYNSDGYGG | 636 | O00571 | |
| GFKYDYAAGGGGGDG | 136 | P31275 | |
| GGGGGGYNRSSGGYE | 226 | P35637 | |
| DGYDGGYGGFDDYGG | 141 | P31942 | |
| GGYLGEQGADYYGGG | 26 | P09016 | |
| MNAGAGYGSYGYGGN | 666 | Q12906 | |
| GGGGSSGYGSYYQGD | 706 | Q12906 | |
| GFGGGGYGGFYNSDG | 631 | O15523 | |
| GFQNRGGGSGGGGNY | 641 | Q9BUJ2 | |
| GGGYQDGGYRDSGFQ | 391 | Q8NCA5 | |
| GGYQGGGYGGFQTSS | 416 | Q8NCA5 | |
| AGGARGAFGYGNGGG | 296 | P0DPA2 | |
| NFGFGDSRGGGGNFG | 206 | P22626 | |
| SGRGFGDGYNGYGGG | 236 | P22626 | |
| GGGNYGSGNYNDFGN | 291 | P22626 | |
| YNAYGGGGGGSSYGG | 231 | Q13151 | |
| GGGGGSSYGGSDYGN | 236 | Q13151 | |
| SSYGGSDYGNGFGGF | 241 | Q13151 | |
| SRGSYGGGDGGYNGF | 256 | P51991 | |
| GGGYDGYNEGGNFGG | 306 | P51991 | |
| GYNEGGNFGGGNYGG | 311 | P51991 | |
| GNFGGGNYGGGGNYN | 316 | P51991 | |
| GNYGGGGNYNDFGNY | 321 | P51991 | |
| SRGGGGYGGSGDGYN | 231 | P09651 | |
| GYGGSGDGYNGFGND | 236 | P09651 | |
| GDGYNGFGNDGGYGG | 241 | P09651 | |
| GYGSGGQGYGNQGSG | 266 | P09651 | |
| GQGYGNQGSGYGGSG | 271 | P09651 | |
| YGGSGSYDSYNNGGG | 281 | P09651 | |
| SYDSYNNGGGGGFGG | 286 | P09651 | |
| GSGSNFGGGGSYNDF | 301 | P09651 | |
| FGGGGSYNDFGNYNN | 306 | P09651 |